Download Anthony Shields, MD, PhD

Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
NAME
POSITION TITLE
Anthony F. Shields, M.D., Ph.D.
eRA COMMONS USER NAME ashields
Professor of Medicine
INSTITUTION AND LOCATION
DEGREE
YEAR(s)
FIELD OF STUDY
Massachusetts Institute of Technology, Cambridge, MA
BS
1974
Biology
Massachusetts Institute of Technology, Cambridge, MA
BS
1974
Chemistry
Harvard Medical School, Boston, MA
MD
1979
Medicine
Massachusetts Institute of Technology, Cambridge, MA
PhD
1979
Cell Biology
A. Personal Statement
The goal of the clinical trials methodology workshop is to instruct and guide faculty in learning the
fundamentals of designing and conducting clinical evaulations using imaging methods. Dr. Shields has
been involved for a long time in laboratory, translational and clinical research and leads efforts by
investigators at Wayne State University/Karmanos Cancer Institute in these arenas. As a fellow he began
work on the development and testing of tracers for use with positron emission tomography (PET) for the
assessment of a variety of tumors (e.g. GI, lung, breast, and prostate cancers) and their response to
treatment. Dr. Shields led the development of FLT {3’-deoxy-3’-fluorothymidine}; a promising tracer for
tumor proliferation, which is being tested in centers worldwide. He has also worked on the development of
18
F- FMAU {1-(2’-deoxy-2’-fluoro-beta-D-arabinofuranosyl)-thymine} to image cellular stress. Dr. Shields is
also on the Steering Committee of the American College of Radiology (ACRIN) and the National Oncology
PET Registry (NOPR) and works to incorporate innovative imaging in the multicenter clinical trials. Dr.
Shields training as a Medical Oncologist provides the insight to guide studies in patients with cancer and
the foresight to design trials that are appropriate. He is the sub-chair for colorectal cancer at the Southwest
Oncology Group (SWOG) and serves on the NCI Colon Task Force, which is charged with overseeing
clinical research studies in colorectal cancer. Dr. Shields is also on the NCI Investigational Drug Steering
Committee. In the clinic, his work concentrates on the treatment of patients with gastrointestinal (GI)
cancer and he continues to develop and lead new clinical trials for GI tumors. Dr. Shields understands the
challenges clinicians and researchers have in guiding and developing new treatments for cancer. As a
clinician and scientist, Dr. Shields has participated in bringing new agents from the laboratory to the clinic.
As an Associate Center Director for Clinical Sciences, and member of the Human Investigation Committee
Medical Investigational Review Board for phase I studies, he helps to oversee a large number of clinical
studies within our Institute and comprehends the complexities and challenges of the approaches to
successful evaluation of new agents.
B. Positions and Experience and Honors
1979 -1981
Residency in Internal Medicine, Univ of Washington School of Medicine, Seattle, WA
1981 -1984 Senior Fellow, Division of Oncology, University of Washington School of Medicine
1985 -1995 Assistant Member, Clinical Res Division, Hutchinson Cancer Research Ctr, Seattle, WA
1987 -1993 Assistant Professor of Medicine, Oncology Division, U of WA, Seattle, WA
1987 -1995 Staff Physician, VA Medical Center, Seattle, Washington
1993 -1995 Associate Professor of Medicine, Div of Oncology, U of WA, Seattle, WA
1995 -1999 Associate Professor, Medicine and Oncology, tenured, Wayne State, Detroit, MI
1995 -2006 Chief, GI Oncology Section, Karmanos Cancer Institute, Harper Hospital/ Detroit Med Ctr
1999 -present Professor, Medicine and Oncology, (tenured) Wayne State U School of Medicine, Detroit, MI
2003 -present Associate Center Director for Clinical Research, Karmanos Cancer Institute
Other Experience
1995 -present Scientific Member, Karmanos Cancer Institute
1997 -present Program Leader, Developmental Therapeutics, Karmanos Cancer Institute
2000, 2004-05 Chair, Michigan Department of Community Health Task Force on Colorectal Cancer
Honors
1983 -1985 National Research Service Award Fellow
1984 -1985 American Cancer Society Junior Faculty Fellow
1999 -2004 Midcareer Investigator Award, National Cancer Institute
2005
Peter Valk Distinguished Clinical Scientist Award, Academy of Molecular Imaging
2005
The European Association of Nuclear Medicine and Springer-Verlag Award - Best Clinical Paper
PHS 398/2590 (Rev. 11/07)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
2007
Wayne State University Distinguished Faculty Fellowship Award
B. Selected peer-reviewed publications (from 101 publications, in chronological order).
Most relevant to the current application
1. Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal cancer with
oxaliplatin and capecitabine: a phase II trial. Cancer, 100:531-7, 2004. PMID: 14745869
2. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, Douglas K, and Shields AF. Imaging
DNA synthesis with 18F-FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med
Mol Imaging, 32:15-22, 2005. The European Association of Nuclear Medicine and Springer-Verlag Award Best Clinical Paper, 2005. PMID: 15586282
3. Sun H, Collins JM, Mangner TJ, Muzik O, Shields AF. Imaging the pharmacokinetics of 18F-FAU in patients
with tumors: PET studies. Cancer Chemother Pharmacol, 57:343-8, 2006. PMID: 16001172
4. Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, Mangner TJ, Heilbrun LK,
Muzik O. Analysis and reproducibility of [18F] 3’-deoxy-3’-fluorothymidine PET imaging in patients with nonsmall cell lung cancer. Clin. Cancer Res, 14:4463-8, 2008. PMID: 18628460
5. Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields, AF. Using 18FFluorodeoxyglucose Positron Emission Tomography (FDG PET) to monitor clinical outcomes in patients
treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol,
Epub Oct 2, 2009. PMID: 19806035
Additional recent publications of importance to the field (in chronological order)
6. Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, Mangner TJ, Heilbrun
LK, Muzik O. A simplified analysis of [18F] 3’-fluorothymidine metabolism and retention. Eur J Nucl Med
Mol Imaging, 32:1269-75, 2005. PMID: 15991018
7. Nimmagadda S, Mangner TJ, Douglas KA, Muzik O, Shields AF. Biodistribution, PET imaging, and
radiation dosimetry estimates of HSV-tk gene expression imaging agent (1-(2'-deoxy-2'-[18F]-fluoro-β-Darabinofuranosyl)-5-iodouracil) in normal dogs. J Nucl Med, 48:655-660, 2007. Society of Nuclear
Medicine Education and Research Foundation, Alavi-Mandell Award, 2008. PMID: 17401105
8. Nimmagadda S, Mangner TJ, Douglas KA, Muzik O, Shields AF. Biodistribution, PET imaging, and
radiation dosimetry estimates of HSV-tk gene expression imaging agent (1-(2'-deoxy-2'-[18F]-fluoro-β-Darabinofuranosyl)-5-iodouracil) in normal dogs. J Nucl Med, 48:655-660, 2007. Society of Nuclear
Medicine Education and Research Foundation, Alavi-Mandell Award, 2008. PMID: 17401105
9. Fletcher FW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold
JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF.
Recommendations for the use of FDG (fluorine-18, (2-[18F]fluoro-2-deoxy-D-glucose) positron emission
tomography in oncology. J Nucl Med, 49:480-508, 2008. PMID: 18287273
10. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE. Impact of positron
emission tomography/computed tomography and positron emission tomography (PET) alone on expected
management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol,
26:2155-61, 2008. PMID: 18362365
11. Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU
reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging, 35:1480-8, 2008. PMID: 18265975
12. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hanna L, Stine SH, Coleman RE. The impact of
Positron Emission Tomography on expected management during cancer treatment: findings of the National
Oncologic PET Registry. Cancer, 115:410-8, 2009. PMID: 19016303
13. Coleman RE, Hillner BE, Shields AF, Duan F, Merlino DA, Hanna L, Stine SH, Siegel BA. PET and
PET/CT reports: observations from the National Oncologic PET Registry. J Nucl Med. 51:158-63, 2010.
Epub Dec 15, 2009. PMID: 20008997
14. Nimmagadda S, Mangner TJ, Lawhorn-Crews JM, Haberkorn U, Shields AF. Herpes simplex virus
thymidine kinase imaging in mice with (1-(2’-deoxy-2’-[18F] fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) and
metabolite (1-(2’-deoxy-2’-[18F] fluoro-1-β-D-arabinofuranosyl)-5-uracil). Eur J Nucl Med Mol Imaging,
36:1987-93, 2009. Epub Jun 9 2009. PMID: 19506865
15. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary
GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced
pancreatic cancer. Invest New Drugs, Epub Jan 27, 2010. PMID: 20107864
PHS 398/2590 (Rev. 11/07)
Page
Continuation Format Page